CytoMed Therapeutics Ltd
NASDAQ:GDTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inspire Medical Systems Inc
NYSE:INSP
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Country Average (15), the stock would be worth $-3.96 (497% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.8 | $1 |
0%
|
| Country Average | 15 | $-3.96 |
-497%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| SG |
C
|
CytoMed Therapeutics Ltd
NASDAQ:GDTC
|
11.8m USD | -3.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 29.5 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 10.4 |
| Median | 15 |
| 70th Percentile | 23.1 |
| Max | 14 028.2 |
Other Multiples
CytoMed Therapeutics Ltd
Glance View
CytoMed Therapeutics Ltd. operates as a biopharmaceutical company. The company employs 27 full-time employees The company went IPO on 2023-04-14. The firm is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. The company is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.
